Accordingly, inhibition of the TLR4/MYD88 pathway in fibrocyte-like synoviocytes has been proposed as a promising therapeutic approach for managing RA (Bartok and Firestein, 2010). Here, MYD88 is linked to rheumatoid arthritis.